What question did this study set out to answer?

Evaluate the clinical impact of voxelotor discontinuation on adults with sickle cell disease previously treated with the medication.

December 8, 2025BloodOpen Access

Impact of voxelotor discontinuation on patients with sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

RMRobert E. MolokieUniversity of Illinois Chicago

Discussion

Member takes

Implication

Retrospective study finds voxelotor withdrawal decreases hemoglobin in adults with sickle cell disease but does not increase hospitalizations or ED visits.

Key Points

Evaluate the clinical impact of voxelotor discontinuation on adults with sickle cell disease previously treated with the medication.
Retrospective study involving 73 adults with sickle cell disease
Data collected on voxelotor dispensing, laboratory values, emergency department visits, and hospitalizations
Statistical analyses included descriptive statistics and comparisons using Chi-square and Wilcoxon signed-rank tests.
54 of 73 prescribed voxelotor initiated therapy; 32 were actively taking it at withdrawal
Median hemoglobin decreased significantly from 8.2 g/dL to 7.7 g/dL after discontinuation
Number of ED visits and hospitalizations remained stable before and after voxelotor withdrawal.

Cite This Study

Robert E. Molokie (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5a2 https://doi.org/10.1182/blood-2025-6150

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study finds voxelotor withdrawal decreases hemoglobin in adults with sickle cell disease but does not increase hospitalizations or ED visits.

Impact of voxelotor discontinuation on patients with sickle cell disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of voxelotor discontinuation on patients with sickle cell disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider